Pfizer Grant Program for RRMM Care Improvement (Italy)

Pfizer has launched a Competitive Grant Program in Italy to fund quality improvement initiatives that enhance the management of Relapsed/Refractory Multiple Myeloma (RRMM) patients treated with BCMA bispecific antibodies.

Organizations can request up to EUR 85,000 (higher budgets possible with strong justification) for projects lasting up to 18 months. The program focuses on clinical process optimization, infection prevention, adverse event management, education, and technology-enabled care improvements.

Program Overview

Funding Organization: Pfizer LLC

Program Type: Competitive Grant Program

Geographic Scope: Italy only

Maximum Funding: EUR 85,000 per project (higher amounts may be considered with strong justification)

Maximum Duration: 18 months

Primary Focus: Quality improvement in RRMM care involving BCMA bispecific antibodies

Clinical Context and Rationale

What Is Multiple Myeloma?

Multiple Myeloma is a hematologic cancer that affects plasma cells in the bone marrow.

It represents approximately 1% of all cancer diagnoses worldwide and accounts for about 1.6% of cancers in men and 1.5% in women in Italy.

What Is Relapsed/Refractory Multiple Myeloma (RRMM)?

Relapsed/Refractory Multiple Myeloma refers to cases where:

• The disease returns after previous treatment (relapsed)

• The disease does not respond to therapy (refractory)

These patients often require advanced and innovative treatment options.

What Are BCMA Bispecific Antibodies?

BCMA (B-cell Maturation Antigen) bispecific antibodies are targeted immunotherapies that:

• Bind to BCMA expressed on myeloma cells

• Simultaneously engage immune cells

• Direct the immune system to attack cancer cells

• Are frequently administered subcutaneously

While highly effective and specific, these therapies require enhanced monitoring and structured care models due to risks such as:

• Infections

• Immune-related adverse events

• Emerging treatment-related toxicities

• Need for multidisciplinary coordination

As their use expands in Italy, quality improvement initiatives are essential to ensure safe and optimal patient outcomes.

Program Objectives

Pfizer aims to support projects that address systemic gaps, educational needs, and operational barriers in RRMM patient management.

Proposals should align with one or more of the following areas:

1. Clinical Process Optimization

• Standardizing care pathways

• Improving monitoring systems

• Enhancing infection prevention protocols

• Strengthening early detection of adverse events

• Improving multidisciplinary collaboration

2. Education and Empowerment

• Training healthcare professionals

• Addressing knowledge gaps in bispecific antibody management

• Empowering patients and caregivers

• Enhancing patient understanding of treatment risks and benefits

3. Technology-Enabled Quality Improvement

• Digital monitoring tools

• Remote patient management systems

• Clinical decision-support tools

• Data-driven quality measurement strategies

Who Is Eligible?

Only organizations located in Italy are eligible.

Eligible applicants include:

• Medical schools

• Dental schools

• Nursing schools

• Allied health professional schools

• Pharmacy schools

• Healthcare institutions

• Professional organizations

• Government agencies

• Other entities with a healthcare improvement mission

Key requirements:

• Funding is awarded only to organizations, not individuals

• Collaborations between institutions are encouraged

• All partners must have clearly defined roles

• The requesting organization must play a central leadership role

• The Project Lead or Principal Investigator must:

  • Be an employee or contractor of the applying organization

  • Belong to an institution legally able to receive funding from Pfizer LLC

Funding Structure

Maximum standard funding: EUR 85,000 per project

Higher budget requests may be considered for:

• Large-scale initiatives

• Highly innovative approaches

• Proposals with strong clinical rationale and detailed cost justification

Maximum project duration: 18 months

Projects must present measurable outcomes and realistic implementation timelines.

Why This Grant Matters

Improves patient outcomes by strengthening therapy management and early complication detection

Supports safe implementation of advanced BCMA-targeted therapies

Encourages structured, multidisciplinary care models in hematology

Addresses systemic gaps in infection prevention and adverse event monitoring

Promotes digital health solutions and data-driven quality improvement

How to Apply

Applicants should follow a structured proposal development process.

Step 1: Identify the Clinical Gap
Clearly define existing challenges in RRMM management involving BCMA bispecific antibodies. Provide supporting institutional data if available.

Step 2: Define Clear Objectives
Set measurable goals such as reduced infection rates, improved adverse event detection time, or enhanced staff knowledge.

Step 3: Develop an Implementation Plan
Outline:

• Project timeline (up to 18 months)

• Key activities

• Roles and responsibilities

• Monitoring and evaluation framework

Step 4: Prepare a Detailed Budget
Align costs with activities. Justify all expenses. Provide additional rationale if requesting more than EUR 85,000.

Step 5: Confirm Institutional Eligibility
Ensure legal capacity to receive funding from Pfizer LLC. Identify the Project Lead and governance structure.

Step 6: Submit the Proposal
Follow Pfizer’s official grant submission platform and guidelines. Ensure alignment with program priorities.

Common Mistakes to Avoid

Submitting applications as individuals instead of institutions

Proposing traditional research trials instead of quality improvement initiatives

Failing to define measurable outcomes

Ignoring infection prevention and adverse event management components

Providing vague or poorly justified budgets

Not demonstrating multidisciplinary collaboration

Strong proposals are structured, outcome-focused, and clearly aligned with program objectives.

Frequently Asked Questions (FAQs)

1. Is this program open outside Italy?
   No. The grant is limited to organizations located in Italy.

2. Can individual physicians apply?
   No. Only organizations can receive funding.

3. What is the maximum funding amount?
   Up to EUR 85,000 per project. Larger budgets may be considered with strong justification.

4. What is the maximum project duration?
   Projects may last up to 18 months.

5. Are research studies eligible?
   The focus is on quality improvement initiatives rather than traditional clinical research.

6. Are collaborations allowed?
   Yes. Collaborative proposals are encouraged if roles are clearly defined and the lead organization plays a key role.

7. What outcomes should projects measure?
   Examples include reduced infection rates, improved adverse event management, better care coordination, enhanced professional training, and improved patient engagement.

Key Definitions

RRMM: Relapsed/Refractory Multiple Myeloma

BCMA: B-cell Maturation Antigen, a protein expressed on myeloma cells

Bispecific Antibodies: Engineered antibodies that bind two different targets simultaneously

Quality Improvement (QI): Structured efforts to enhance healthcare processes and outcomes

Subcutaneous Administration: Delivery of medication under the skin

Conclusion

The Pfizer Competitive Grant Program in Italy provides targeted funding to improve the management of RRMM patients treated with BCMA bispecific antibodies.

By prioritizing clinical process optimization, education, infection prevention, multidisciplinary coordination, and technology-enabled quality improvement, the program aims to enhance patient safety and treatment outcomes.

Eligible Italian healthcare institutions have a clear opportunity to design measurable, scalable initiatives within an 18-month framework and strengthen the national standard of RRMM care.